Author

G. Procopio

h-index 10 View on Semantic Scholar

We have 5 of 71 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Lynch syndrome–associated urothelial carcinoma: clinical and molecular findings from a single-institution cohort

Lynch syndrome–associated urothelial carcinoma (LS-UC) is a rare and undercharacterized clinical entity. While FGFR3 alterations are well described in sporadic urothelial carcinoma, their prevalence and clinical implications in LS-UC remain unclear. We aimed to provide a comprehensive clinical and molecular characteriz...

A. Rametta, M. Barella, A. Scardino et al. · Familial Cancer · 0 citations

Editorial Sep 2026

Growth in oncology clinical trials and decline of independent research: Insights from the 22nd AIFA National Report on clinical trials.

The 22nd National Report on Clinical Trials of Medicinal Products published by the Italian Medicines Agency (AIFA) in July 2026 highlights contrasting trends in Italian clinical research. In 2024, 669 prospective clinical trials were authorized, the highest number recorded in the last three years. Oncology and hemato-o...

C. Cagnazzo, S. Stacchiotti, G. Procopio · Tumori · 0 citations

Review Open access Sep 2026

Global management of drug–drug interaction in patients with prostate cancer: international survey by Meet-URO group and ONCOassist

Abstract Background Patients with prostate cancer (PC) frequently receive multiple medications for comorbidities, increasing the risk of drug–drug interactions (DDIs). Despite guidelines highlighting DDI relevance, data on real-world management are limited. This international survey aimed to characterize current practi...

A. A. Valsecchi, M. Maffezzoli, M. Cursano et al. · The Oncologist · 0 citations

Review Open access Aug 2026

Molecular biomarkers in metastatic clear cell renal cell carcinoma treated with first-line immune combinations: a systematic review of phase III randomized clinical trials by Meet-URO group

Immune checkpoint inhibitor (ICI)–based combinations represent the standard first-line treatment for metastatic clear cell renal cell carcinoma (mRCC), although robust biomarkers for treatment selection remain undefined. We conducted a systematic review to identify biomarkers assessed in randomized clinical trials (RCT...

A. A. Valsecchi, M. Maffezzoli, M. Cursano et al. · Cancer Metastasis Review · 0 citations

Open access Aug 2026

Reducing the burden of active surveillance monitoring examinations in prostate cancer: Insights from real-world data to inform clinical practice.

A model using simple, routine parameters and PSA doubling time can identify those at minimal risk of reclassification, enabling a safe reduction in biopsy intensity, and advocates for a risk-adaptive AS protocol.

C. Marenghi, F. Badenchini, B. Avuzzi et al. · Tumori · 0 citations